GLP-1 Weight Management for Pharmacies: Platform Requirements for Safe Prescribing

The demand for GLP-1 receptor agonist weight management services in UK pharmacies is unprecedented. Since NICE approved semaglutide (Wegovy) for chronic weight management in March 2023 (Technology Appraisal TA875), and with tirzepatide (Mounjaro) receiving MHRA authorisation for weight management, pharmacist independent prescribers have found themselves at the centre of one of the fastest-growing clinical services in UK healthcare.

But the clinical complexity of GLP-1 prescribing, dose titration schedules, BMI eligibility thresholds, cardiovascular risk assessment, ongoing monitoring, demands more than a basic consultation platform. This guide details the specific platform requirements for running a safe, compliant, and scalable weight management service.

The Clinical Workflow: Why Generic Platforms Fall Short

A standard private prescribing consultation follows a linear path: assess, prescribe, discharge. GLP-1 weight management is fundamentally different, it is a longitudinal service requiring repeated patient contacts over months or years:

1. Initial eligibility screening, BMI ≥30 kg/m² (or ≥27 with weight-related comorbidities per NICE TA875)
2. Comprehensive clinical assessment, cardiovascular history, thyroid function, pancreatitis risk, mental health screening, medication review
3. Initiation at lowest dose, semaglutide 0.25mg weekly or tirzepatide 2.5mg weekly
4. Dose titration, scheduled increases every 4 weeks (semaglutide: 0.25→0.5→1→1.7→2.4mg; tirzepatide: 2.5→5→7.5→10→12.5→15mg)
5. Regular monitoring, weight, BMI, adverse effects, adherence, psychological wellbeing at each titration point
6. Ongoing management, maintenance dose prescribing, 12-week efficacy reviews, annual comprehensive assessments

A platform that only handles one-off consultations cannot manage this longitudinal journey. You need a system that tracks where each patient is in their treatment pathway and prompts the right clinical actions at the right time.

Platform Feature Requirements for GLP-1 Services

Eligibility Screening Automation

Before a patient reaches a prescriber, the platform should automatically screen for eligibility based on NICE criteria. This means:

• BMI calculation from self-reported height and weight (with verification at consultation)
• Automatic exclusion flagging: personal or family history of medullary thyroid carcinoma, MEN2, active pancreatitis, pregnancy/breastfeeding
• Comorbidity identification: type 2 diabetes, hypertension, obstructive sleep apnoea, NAFLD, which may support prescribing at BMI 27-29.9
• Previous weight management attempts documentation (NICE requires evidence of prior lifestyle interventions)

This pre-screening saves prescriber time, patients who clearly do not meet criteria are redirected before consuming a consultation slot.

Dose Titration Tracking

The most common clinical governance failure in GLP-1 services is inadequate titration management. Your platform must:

• Record the current dose for each patient and calculate the next scheduled increase
• Alert the prescriber when a patient is due for titration review
• Prevent dose increases without documented clinical review (a safety net against administrative errors)
• Record adverse effects at each titration point, GI symptoms (nausea, vomiting, diarrhoea) are expected but must be documented and assessed for severity
• Flag patients who have been on the same dose for longer than expected without review

Weight and Outcome Tracking

NICE TA875 includes a stopping rule: treatment should be discontinued if patients have not achieved at least 5% weight loss after 6 months on the maintenance dose. Your platform needs:

• Baseline weight and BMI recording at initiation
• Weight tracking at every contact with automatic percentage-loss calculation
• Automated 6-month efficacy flag: has this patient achieved the 5% threshold?
• Visual weight trajectory graphs for clinical review and patient engagement

Contraindication and Interaction Alerts

GLP-1 agonists have specific safety considerations that your platform should actively flag:

• Pancreatitis risk, history of pancreatitis, heavy alcohol use, very high triglycerides
• Thyroid considerations, family history of MTC, unexplained thyroid nodules
• Insulin and sulfonylurea interactions, risk of hypoglycaemia when combined with GLP-1 agonists in diabetic patients
• Renal impairment, GI adverse effects can cause dehydration and acute kidney injury in susceptible patients
• Gastroparesis, GLP-1 agonists delay gastric emptying and are contraindicated in severe gastroparesis

Patient Communication and Retention

GLP-1 treatment is a long-term commitment. Patients who disengage mid-titration represent both a clinical concern (abrupt cessation, potential rebound weight gain) and a business concern (lost revenue). Platform features that support retention:

• Automated appointment reminders for titration reviews
• Patient-facing progress dashboards showing weight loss trajectory
• Educational content delivery at appropriate points (e.g., managing nausea during dose increases)
• Missed appointment follow-up, automatic outreach when patients fail to attend scheduled reviews

Clinical Governance for GLP-1 Services

The GPhC has increased scrutiny of pharmacy weight management services following reports of inappropriate prescribing. Your governance framework must demonstrate:

• Prescribing within competence, documented training in obesity management and GLP-1 pharmacology. The RPS Faculty has a competency framework for prescribers in this area.
• Adherence to NICE guidance, eligibility criteria, stopping rules, and monitoring schedules must match published recommendations
• Clinical audit, regular review of prescribing patterns, patient outcomes, adverse effect rates, and dropout analysis
• Shared care communication, notifying patient GPs of GLP-1 initiation, particularly regarding interactions with existing medications
• Supply chain integrity, documented sourcing through licensed wholesalers only (MHRA requirement)

The Business Case: Revenue Potential

GLP-1 weight management services generate recurring revenue through the titration and maintenance phases. Without citing specific revenue figures (which vary by pricing model and patient volume), the structural advantages are clear:

• Patients require monthly consultations during titration (typically 4-5 months)
• Maintenance patients require 3-monthly reviews (ongoing)
• Each contact is a billable consultation
• High patient retention when services are well-run (patients see measurable results)
• Word-of-mouth referrals are strong in weight management (visible results drive recommendations)

A flat-rate platform like RxSure at £199/month means your platform cost remains fixed regardless of how many weight management patients you take on. No per-prescription fees eating into margins on every follow-up.

Frequently Asked Questions

Do I need specific training before prescribing GLP-1s?

Yes. While your IP qualification gives you legal authority to prescribe any medicine within your competence, GLP-1 weight management requires specific knowledge. Complete accredited training in obesity management, providers include CPPE (Centre for Pharmacy Postgraduate Education), Buttercups Training, and various HEE-funded programmes. Document this training in your CPD portfolio and include it in your scope of practice declaration.

Can I prescribe GLP-1s for patients with BMI 25-27?

NICE TA875 specifies BMI ≥30 (or ≥27 with at least one weight-related comorbidity) as the eligibility threshold for semaglutide. Prescribing below these thresholds is outside NICE guidance and would require exceptional clinical justification documented in your records. Most governance frameworks and insurers would not support routine prescribing below these thresholds.

What about the supply issues with semaglutide?

Global demand for semaglutide has created intermittent supply constraints. Your platform should track patient dose levels so you can proactively manage supply, ordering the correct pen strengths in advance rather than reactively. When stock is limited, the platform should help you prioritise existing patients on treatment over new initiations, preventing the clinical risk of treatment interruption.

Should I offer tirzepatide as well as semaglutide?

Offering both gives patients and prescribers choice. Tirzepatide (dual GIP/GLP-1 agonist) has demonstrated superior weight loss in head-to-head trials (SURMOUNT vs STEP studies), though both are clinically effective. Having both on your formulary also provides a switching option if a patient does not tolerate one molecule. Ensure your training covers both agents and your platform supports the different titration schedules.

How does RxSure support weight management services specifically?

RxSure’s platform includes structured consultation templates, patient tracking across multiple appointments, and customisable pre-screening questionnaires that can be configured for weight management eligibility. The flat pricing model means adding weight management patients does not increase your platform costs, whether you run 10 or 200 weight management consultations per month.

References

1. NICE. Technology Appraisal TA875: Semaglutide for managing overweight and obesity. March 2023. nice.org.uk
2. MHRA. Regulatory approval of tirzepatide (Mounjaro) for weight management. 2023. gov.uk
3. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. NEJM. 2022;387:205-216. (SURMOUNT-1 trial)
4. General Pharmaceutical Council. Standards for Registered Pharmacies. 2024. pharmacyregulation.org
5. Royal Pharmaceutical Society. Competency Framework for All Prescribers. 2021. rpharms.com